Reported 3 months ago
BioNTech's cancer drug candidate BNT111 demonstrated significant improvement in response rates for patients with advanced melanoma in a Phase 2 trial, achieving its primary endpoint. The trial showed that BNT111, when combined with the PD-1 inhibitor cemiplimab, had a statistically significant higher overall response rate compared to historical control data. This marks a shift in BioNTech's focus towards cancer drug development amidst a decline in its COVID-19 vaccine business.
Source: YAHOO